{"title":"Pancreatic Mixed Acinar-neuroendocrine Carcinoma in a Patient With a Germline <i>PTEN</i> Variant: A Case Report and Genomic Literature Review.","authors":"Yosuke Saito, Shuhei Suzuki, Tomomi Sanomachi, Kaho Kato, Hiroya Otake, Yuko Nishise, Yuta Yamada, Koki Saito, Koshi Takahashi, Ryosuke Kumanishi, Tadahisa Fukui, Takashi Yoshioka","doi":"10.21873/invivo.13921","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Cowden syndrome (CS)/PTEN hamartoma tumor syndrome (PHTS) is a hereditary disorder caused by germline <i>PTEN</i> variants. While patients with CS/PHTS have increased risk of various cancers, pancreatic cancer is not typically associated with this syndrome. We report a rare case of pancreatic mixed acinar-neuroendocrine carcinoma in a patient with a germline <i>PTEN</i> variant, aiming to understand its molecular characteristics and clinical implications.</p><p><strong>Case report: </strong>A male in his late 40s presented with pancreatic cancer and hepatic metastases. His medical history included thyroid cancer and familial gastrointestinal malignancies. Liver biopsy revealed mixed acinar-endocrine carcinoma. Cancer genome profiling identified pathogenic variants in <i>GNAS</i> and <i>TP53</i>, along with a germline <i>PTEN</i> variant (V201fs*1), leading to a diagnosis of CS. Notably, <i>KRAS</i> mutations, commonly found in pancreatic cancer, were absent. The patient showed extreme resistance to multiple chemotherapy regimens, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, and cisplatin plus etoposide, resulting in rapid clinical decline.</p><p><strong>Conclusion: </strong>This case highlights a rare presentation of pancreatic cancer in CS/PHTS with distinct molecular and histological features. The absence of <i>KRAS</i> mutation and presence of germline <i>PTEN</i> variant may have contributed to the aggressive clinical course and treatment resistance. These findings underscore the need for further research into the molecular mechanisms of PTEN-associated pancreatic cancers and the development of targeted therapeutic strategies.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1173-1181"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884457/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13921","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Cowden syndrome (CS)/PTEN hamartoma tumor syndrome (PHTS) is a hereditary disorder caused by germline PTEN variants. While patients with CS/PHTS have increased risk of various cancers, pancreatic cancer is not typically associated with this syndrome. We report a rare case of pancreatic mixed acinar-neuroendocrine carcinoma in a patient with a germline PTEN variant, aiming to understand its molecular characteristics and clinical implications.
Case report: A male in his late 40s presented with pancreatic cancer and hepatic metastases. His medical history included thyroid cancer and familial gastrointestinal malignancies. Liver biopsy revealed mixed acinar-endocrine carcinoma. Cancer genome profiling identified pathogenic variants in GNAS and TP53, along with a germline PTEN variant (V201fs*1), leading to a diagnosis of CS. Notably, KRAS mutations, commonly found in pancreatic cancer, were absent. The patient showed extreme resistance to multiple chemotherapy regimens, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, and cisplatin plus etoposide, resulting in rapid clinical decline.
Conclusion: This case highlights a rare presentation of pancreatic cancer in CS/PHTS with distinct molecular and histological features. The absence of KRAS mutation and presence of germline PTEN variant may have contributed to the aggressive clinical course and treatment resistance. These findings underscore the need for further research into the molecular mechanisms of PTEN-associated pancreatic cancers and the development of targeted therapeutic strategies.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.